Refine by
Drug Candidate Suppliers & Manufacturers
130 companies found
Premium
based inFramingham, MASSACHUSETTS (USA)
SCIEX empowers you to solve the most impactful analytical challenges in quantitation and characterization in environmental testing. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field ...
based inBasel, SWITZERLAND
CanVirex is a spin-off from the Heidelberg University Hospital, founded in 2017 in Basel, Switzerland. The company develops novel immunotherapeutics for the treatment of cancer and has recently committed to using its unique technology to develop a ...
based inBuk-gu, SOUTH KOREA
JD Bioscience (JDB) is a group of experts in small molecule-based novel drug development. JD Bioscience was established by a team of highly experienced medicinal chemists, biologists, and clinicians in the field of endocrine and metabolic diseases. ...
NASH, an advanced form of non-alcoholic fatty liver disease (NAFLD), can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Genetic factors, environmental factors, and microbiome alterations are mainly involved in disease ...
based inMississauga, ONTARIO (CANADA)
Award-winning, Clinical Stage/Life-Sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The company is targeting anxiety, depression, ...
based inMadison, WISCONSIN (USA)
InvivoSciences, Inc. (IVS) is a precision medicine company personalizing the drug development process by introducing patient-derived and gene-edited human samples, including 3D engineered microtissues. Our unique integration of cell & tissue ...
Human engineered tissue (EHT)-based high content analysis can be applied to drug discovery projects at their compound screening and lead optimization stage. Mass-produced human engineered tissues will recapitulate physiological functions of native ...
based inStockholm, SWEDEN
IBT is a pharmaceutical company with its registered office in Stockholm with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. IBT is currently developing its ...
IBP-9414 for the prevention of necrotizing enterocolitis (NEC) contains the active substance Lactobacillus reuteri, which is a co-evolved human bacterial strain naturally present in breast milk. Lactobacillus reuteri is a live bacteria known to be ...
based inBaltimore, MARYLAND (USA)
Sapio Sciences is a leading provider of Laboratory Management, Electronic Lab Notebook, and Knowledge Management Solutions. Sapio is at the forefront of the Digital Lab with its science-aware platform for managing all your life science data with its ...
With our LIMS configurable technology and workflow templates, projects are completed in a fraction of the time and cost of standard LIMS ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
Colorectal cancer (CRC) is the second-most common cancer diagnosed in women and third-most in men. Based upon five-year survival rates, chances of becoming cured remain to be approximately 65%. Therapies targeting immunological checkpoints, or more ...
based inGhent, BELGIUM
ExeVir is a clinical stage company developing single-domain antibody-based therapies that help patients ward off viral infections. Our lead candidate XVR011 is in accelerated development as a COVID-19 ...
based inHayward, CALIFORNIA (USA)
BioAssay Systems develops and markets innovative and high-throughput assay solutions to satisfy the ever increasing demands of the life sciences industry. The founders of BioAssay Systems have over 50 years of extensive experience in modern drug ...
based inMalmö, SWEDEN
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Oncoral is a novel oral irinotecan tablet in ...
based inSchlieren, SWITZERLAND
InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Our robust and highly physiologically relevant suite of ...
An in vitro PDX model with in vivo-like heterogeneity. 3D InSight™ Tumor Microtissues from Patient-Derived Xenografts (PDX) are custom assay-ready 3D in vitro tumor models engineered to reflect complex tumor biology without the use of ...
based inNewtown, PENNSYLVANIA (USA)
Formely known as Onconova Therapeutics, Inc. Traws Pharma is a clinical stage biopharmaceutical company developing small molecule oral product candidates for respiratory viral diseases and cancer. In the viral respiratory disease space, Traws Pharma ...
based inTübingen, GERMANY
Acousia is committed to identifying and developing novel compounds (small molecules) to preserve and enhance natural hearing for patients suffering from sensorineural hearing loss (SNHL), which make up over 90 percent of those affected by hearing ...
With its first clinical study underway, Acousia is taking significant strides towards achieving its goal of developing novel medicines that enhance and preserve natural hearing for patients with ...
based inLondon, UNITED KINGDOM
At Benevolent we build technology in the service of science - to augment human intelligence and inspire the discovery of new medicines for the thousands of diseases that have no treatment. Building the right team is an art not a science. We strive ...
Progress so far: For our most advanced UC programme, we identified an AI-generated target with novel mechanisms of action in UC, and rapidly delivered a candidate drug to IND/CTA-enabling ...
based inCharlottesville, VIRGINIA (USA)
LumaCyte is an advanced research and bioanalytics instrumentation company that produces label-free, single cell analysis instrumentation where the use of antibody or genetic labeling is not required for cellular analysis. This revolutionary ...
based inSeongnam-si, SOUTH KOREA
LISCure Biosciences Provides Novel Therapeutics to Patients with Refractory Diseases Using the LMT Platform. LISCure is developing the world’s first injectable immuno-oncology program using non-pathogenic microorganisms. We focus on the development ...
The LMT (LISCure Microbiology-based Technology) platform is an innovative tool to keep discovering and analyzing microbial and genome-based drug candidates. LMT (LISCure Microbiology-based Technology) Platform ...
based inBerlin, GERMANY
3B Pharmaceuticals GmbH (3BP) is a German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need. As a leader in peptide discovery and optimization, 3BP has built a ...
3B Pharmaceuticals have built a drug discovery platform extending from hit identification to early clinical development. Several drug candidates developed through our platform already have been ...
based inLoos, FRANCE
GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases. Our translational disease-driven research approach is based on strong expertise, featuring in-house knowledge of ...
Primary Biliary Cholangitis (PBC) is a chronic disease in which bile ducts in the liver are gradually destroyed.1 The damage to bile ducts can inhibit the liver’s ability to rid the body of toxins, and can lead to cirrhosis. Targeting PPAR ...
based inIllkirch-Graffenstaden, FRANCE
Inoviem, a bioanalytical Contract Research Organization (CRO), enables drug developers to gain higher precision in the understanding of a compound’s clinical Mode of Action (MoA), so that a drug candidate can move rapidly to clinical trials. ...
Identify the mode of action of your compound with NPOT® technology; NPOT technology is a unique heterogeneous assembly method for conducting extensive identification of all proteins (together with their native structure) involved in drug-target ...